Kalaris Therapeutics (KLRS) risk factors, FY2024 10-K

Risks Related to the Merger

1. 01The exchange ratio set forth in the merger agreement is not adjustable based on the market price of AlloVir’s common stock, so the merger consideration at the closing of the merger may have a greater or lesser value than at the time the merger agreement was signed
2. 02Failure to complete the merger may result in either Kalaris or AlloVir paying a termination fee to the other party, and could harm AlloVir’s common stock price and future business and operations of each company
3. 03substantial costs related to the merger may be incurred by either party, such as financial advisor, legal and accounting fees, a majority of which must be paid even if the merger is not completed
4. 04If the conditions to the merger are not satisfied or waived, the merger may not occur
5. 05The merger may be completed even though certain events occur prior to the closing of the merger that materially and adversely affect AlloVir or Kalaris
6. 06any specific action taken (or omitted to be taken) by AlloVir or Kalaris, as applicable, at or with the express written consent of the other party (which shall include any action taken (or omitted to be taken) that is expressly required to be taken by the merger agreement)
7. 07Transfers of the combined company’s securities utilizing Rule 144 of the Securities Act may be limited
8. 08AlloVir’s disposal of its historical assets and operations in connection with the proposed merger with Kalaris has made AlloVir a shell company. As a result, AlloVir is subject to more stringent reporting requirements, offering limitations and resale restrictions
9. 09AlloVir’s directors and executive officers and those of Kalaris may have interests in the merger that are different from, or in addition to, the interests of AlloVir’s other stockholders generally
10. 10compensated as non-employee directors of the combined company pursuant to the combined company’s non-employee director compensation policy that is expected to become effectives as of the closing of the merger
11. 11AlloVir’s stockholders and Kalaris’ stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger
12. 12If the merger is not completed, AlloVir’s stock price may decline significantly
13. 13period-to-period fluctuations in financial results
14. 14The market price of the combined company’s common stock following the merger may decline as a result of the merger
15. 15the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts
16. 16Raising additional capital may cause dilution to the combined company’s stockholders, restrict its operations or require it to relinquish rights to its technologies or product candidates
17. 17During the pendency of the merger, AlloVir and Kalaris may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the merger agreement, which could adversely affect their respective business prospects
18. 18Certain provisions of the merger agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the merger agreement
19. 19Because the lack of a public market for Kalaris’ capital stock makes it difficult to evaluate the fair market value of Kalaris’ capital stock, the value of the AlloVir’s common stock to be issued to Kalaris stockholders may be more or less than the fair market value of Kalaris’ capital stock
20. 20Stockholder litigation could prevent or delay the consummation of the merger or otherwise negatively impact AlloVir’s, Kalaris’ or the combined company’s business, operating results and conditions
21. 21AlloVir’s ability to consummate the merger depends on AlloVir’s ability to retain the employees required to consummate such transaction

Risks Related to AlloVir

1. 22AlloVir may not be successful in consummating the merger
2. 23Although there can be no assurance that the merger will be completed, the negotiation and consummation of the merger will require significant time on the part of AlloVir’s management, and the diversion of management’s attention may disrupt AlloVir’s business
3. 24Any of the foregoing risks could have a material adverse effect on AlloVir’s business, financial condition and prospects
4. 25AlloVir’s cash preservation activities, including the workforce reduction plan, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt AlloVir’s business
5. 26AlloVir may become involved in litigation, including securities class action litigation, that could divert management’s attention and harm AlloVir’s business, and insurance coverage may not be sufficient to cover all costs and damages

Risks Related to Financial Condition

1. 27AlloVir is a clinical-stage cell therapy company and it has incurred net losses since its inception. AlloVir anticipates that it will continue to incur significant losses for the foreseeable future, and may never achieve or maintain profitability
2. 28acquires or in-license other product candidates and technologies
3. 29AlloVir has a limited operating history, which may make it difficult to evaluate the success of its business to date and to assess its future viability

Risks Related to Capital Needs

1. 30AlloVir will need substantial additional funding, and if it is unable to raise capital when needed, it could be forced to delay, reduce or eliminate its product discovery and development programs or commercialization efforts
2. 31the ongoing costs of operating as a public company

Risks Related to Sales, Marketing and Competition

1. 32AlloVir faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than it does
2. 33If AlloVir is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell its product candidates, it may be unable to generate any revenue
3. 34The occurrence of any event or penalty described above may inhibit AlloVir’s ability to successfully commercialize its products

Risks Related to Business Development and Commercialization

1. 35AlloVir may not successfully identify, acquire, develop or commercialize new potential product candidates
2. 36AlloVir’s commercial success depends upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics
3. 37Even if AlloVir is able to commercialize its product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which it seeks to commercialize its products, which could harm its business
4. 38AlloVir obtains regulatory approval, and ultimately its ability to successfully commercialize any product candidate for which it obtains regulatory approval
5. 39AlloVir must complete clinical testing before it can seek regulatory approval and begin commercialization of any of its product candidates
6. 40Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for AlloVir to obtain regulatory approval of and commercialize its product candidates and affect the prices it may obtain
7. 41enacted and future legislation please see “AlloVir’s Business—Government Regulation—Healthcare Reform” in this Annual Report on Form 10-K
8. 42the availability of capital
9. 43Price controls may be imposed in foreign markets, which may adversely affect AlloVir’s future profitability
10. 44AlloVir expects the product candidates it develops will be regulated biologics and therefore they may be subject to competition sooner than anticipated
11. 45AlloVir’s relationships with customers, third-party payors, physicians and healthcare providers will be subject to applicable anti-kickback, fraud and abuse, and other laws and regulations, which could expose it to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits
12. 46Changes in and failures to comply with U.S. federal and state and foreign privacy and data protection laws, regulations and standards may adversely affect AlloVir’s business, operations and financial performance
13. 47Artificial intelligence presents risks and challenges that can impact AlloVir’s business including by posing security risks to its confidential information, proprietary information, and personal data
14. 48Certain of AlloVir’s directors and officers may have actual or potential conflicts of interest because of their positions with ElevateBio
15. 49Should AlloVir resume development of its product candidates, it may need to grow the size of its organization, and it may experience difficulties in managing this growth
16. 50expanding AlloVir’s facilities
17. 51AlloVir’s employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for it and harm its reputation

Risks Related to AlloVir’s Business

1. 52AlloVir’s internal computer systems, or those used by its third-party CROs or other contractors or consultants, may fail or suffer from cybersecurity incidents or breaches, which could result in a material disruption of the development programs of its product candidates
2. 53Business disruptions could seriously harm AlloVir’s future revenue and financial condition and increase its costs and expenses
3. 54Changes in U.S. or foreign tax law or changes in AlloVir’s effective tax rates could adversely affect its business and financial condition
4. 55AlloVir’s ability to use its net operating loss carryforwards and other tax attributes may be limited
5. 56Unstable market, economic or geopolitical conditions may have serious adverse consequences on AlloVir’s business, financial condition and stock price
6. 57Furthermore, AlloVir’s stock price may decline due in part to the volatility of the stock market and the general economic downturn

Risks Related to AlloVir’s Intellectual Property if the Merger is not Completed

1. 58The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is highly uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation
2. 59AlloVir may not be able to protect its intellectual property rights throughout the world
3. 60any of its partners are forced to grant a license to third parties under patents relevant to its business, or if it or its partners are prevented from enforcing patent rights against third parties, its competitive position may be substantially impaired in such jurisdictions
4. 61AlloVir has in-licensed a significant portion of its intellectual property from its partners, including BCM. If AlloVir breaches any of its license agreements with these partners, it could lose the ability to continue the development and potential commercialization of one or more of its product candidates
5. 62If AlloVir’s trademarks and trade names are not adequately protected, then it may not be able to build name recognition in its markets of interest and its business may be adversely affected
6. 63If AlloVir is unable to protect the confidentiality of its trade secrets and other proprietary information, the value of its technology could be materially adversely affected and its business could be harmed
7. 64information could enable competitors to quickly duplicate or surpass its technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with its product candidates, thus eroding its competitive position in the market

Risks Related to Patents

1. 65Obtaining and maintaining AlloVir’s patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and its patent protection could be reduced or eliminated for non-compliance with these requirements
2. 66Changes in U.S. or foreign patent laws could diminish the value of patents in general, thereby impairing AlloVir’s ability to protect its products

Risks Related to AlloVir’s Dependence on Third Parties if the Merger is Not Completed

1. 67AlloVir depends substantially on intellectual property licensed from third parties, including BCM, and termination of any of these licenses could result in the loss of significant rights, which would harm its business
2. 68the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by its licensors and it and its partners
3. 69AlloVir may not realize the benefits of strategic alliances that it may form in the future or of potential future product acquisitions or licenses

Risks Related to Clinical Development

1. 70maintaining and growing an organization of scientists and functional experts who can develop and commercialize its products and technology
2. 71with substantial evidence gathered in preclinical studies and clinical trials, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency
3. 72its failure to obtain and retain accurate data in its clinical trials

Risks Related to the Industry

1. 73developing therapies for types of diseases beyond those initially addressed by its current product candidates
2. 74AlloVir cannot be sure that the manufacturing processes used in connection with its T cell immunotherapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, comparable to those T cells produced by its partners historically, scalable or profitable
3. 75Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for AlloVir’s product candidates would substantially harm its business
4. 76changes in governmental regulations or administrative actions, failure by it or third parties to comply with regulatory requirements, or lack of adequate funding to continue a clinical trial
5. 77clinicians’ and patients’ perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new product candidates that may be approved for the indications AlloVir is investigating
6. 78AlloVir currently relies on CROs, other vendors and clinical trial sites to ensure the proper and timely conduct of its clinical trials, and while AlloVir has agreements governing their committed activities, AlloVir has limited influence over their actual performance
7. 79experience damage to its reputation
8. 80Interim, “topline” or preliminary data from AlloVir’s clinical trials that it may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
9. 81Should AlloVir resume development of its product candidates, it may not be able to obtain or maintain orphan drug designation to its product candidates, or to obtain and maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
10. 82the first applicant cannot supply enough orphan medicinal product

Risks Related to Litigation if the Merger is Not Completed

1. 83AlloVir may be at an increased risk of securities class action litigation
2. 84Product liability lawsuits against AlloVir could cause it to incur substantial liabilities and to limit commercialization of any products that it may develop
3. 85a decline in AlloVir’s share price

Risks Related to Intellectual Property Litigation

1. 86If AlloVir is sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay its development and commercialization efforts
2. 87AlloVir may face claims that it misappropriated the confidential information or trade secrets of a third party. If AlloVir is found to have misappropriated a third party’s trade secrets, it may be prevented from further using these trade secrets, which could limit its ability to develop its product candidates
3. 88AlloVir may become involved in lawsuits to protect or enforce its intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of its business
4. 89using the technology at issue on the grounds that its patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of AlloVir’s patents at risk of being invalidated, held unenforceable or interpreted narrowly
5. 90AlloVir may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that its employees have wrongfully used or disclosed alleged trade secrets of their former employers

Risks Related to Manufacturing if the Merger is Not Completed

1. 91ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies
2. 92Developing advanced manufacturing techniques and process controls is required to fully utilize AlloVir or its partner’s facility. Without further investment, advances in manufacturing techniques may render AlloVir or its partner’s facility and equipment inadequate or obsolete

Risks Related to Third Party Manufacturing

1. 93AlloVir and its third-party partners are subject to a multitude of manufacturing risks, any of which could substantially increase its costs and limit supply of its product candidates
2. 94Concurrently with the license of AlloVir’s existing product candidates, it acquired manufacturing process know-how and, in some cases, inventory of process intermediates and clinical materials from its partners
3. 95Maintaining clinical and commercial timelines is dependent on AlloVir’s end-to-end supply chain network to support manufacturing; if it experiences problems with its third party suppliers, the development and potential commercialization of its product candidates may be delayed
4. 96If AlloVir is not able to successfully transfer and produce comparable product candidates, its ability to further develop and manufacture its product candidates may be negatively impacted
5. 97AlloVir is dependent on a limited number of suppliers and, in some instances, a sole supplier, for some of its components and materials used in its product candidates
6. 98fluctuation in delivery by its suppliers due to changes in demand from it or their other customers
7. 99If AlloVir and its third-party manufacturers fail to comply with environmental, health and safety laws and regulations, AlloVir could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business
8. 100If AlloVir’s sole raw material suppliers, clinical or commercial drug product manufacturing facility is damaged or destroyed or production at these facilities is otherwise interrupted, its business would be negatively affected
9. 101AlloVir does not know whether an active, liquid and orderly trading market will develop for its common stock or what the market price of its common stock will be and, as a result, it may be difficult for its stockholders to sell shares of its common stock
10. 102The trading price of AlloVir’s common stock may be volatile
11. 103other events or factors, many of which are beyond AlloVir’s control
12. 104In accordance with Nasdaq Listing Rule 5810(c)(3)(A), AlloVir has been provided an initial period of 180 calendar days, or until August 7, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement
13. 105On February 4, 2025, AlloVir received a letter from the Staff, notifying it that, for the last 11 consecutive business days, its common stock had maintained the Minimum Bid Price Requirement and accordingly regained compliance with Listing Rule 5450(a)(1) and this matter is now closed
14. 106AlloVir’s principal stockholders and management own a significant percentage of its stock and will be able to exert significant influence over matters subject to stockholder approval
15. 107Raising additional capital may cause dilution to AlloVir’s existing stockholders, restrict its operations or require it to relinquish rights to its product candidates on terms that are unfavorable to it
16. 108Future sales and issuances of AlloVir’s common stock or rights to purchase common stock, including pursuant to the 2020 Stock Option and Grant Plan (the “2020 plan”), could result in additional dilution of the percentage ownership of its stockholders and could cause its stock price to fall
17. 109Pursuant to the 2020 plan, its management is authorized to grant stock options to its employees, directors, and consultants
18. 110AlloVir does not intend to pay dividends on its common stock, so any returns will be limited to the value of its stock
19. 111AlloVir is an emerging growth company and a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make its common stock less attractive to investors
20. 112which requires the market value of its common stock that is held by non-affiliates to exceed $700 million as of the prior June 30th, and (2) the date on which it has issued more than $1 billion in non-convertible debt during the prior three-year period
21. 113AlloVir incurs significant increased costs as a result of operating as a public company, and its management is required to devote substantial time to new compliance initiatives
22. 114Sales of a substantial number of shares of AlloVir’s common stock by its existing stockholders in the public market could cause its stock price to fall
23. 115AlloVir has broad discretion over the use of its cash and cash equivalents and may not use them effectively
24. 116Anti-takeover provisions under AlloVir’s charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of its common stock and may prevent or frustrate attempts by its stockholders to replace or remove its current management
25. 117the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock
26. 118If AlloVir fails to establish and maintain proper and effective internal control over financial reporting, its operating results and its ability to operate its business could be harmed
27. 119AlloVir’s business, its stock price and trading volume could decline